# SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis

> **NCT07495995** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cedars-Sinai Medical Center** · enrollment: 94 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

## Interventions

- **DRUG:** S-adenosyl-L-methionine (SAMe)
- **OTHER:** Placabo

## Key facts

- **NCT ID:** NCT07495995
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07495995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07495995, "SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07495995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*